Blocking 5-HT2 receptor restores cardiovascular disorders in type 1 experimental diabetes

José-Ángel García-Pedraza¹,², Pedro Ferreira-Santos¹,², Rubén Aparicio¹,², María-José Montero¹,² & Asunción Morán¹,²

This study aimed to determine whether the serotonergic modulation, through selective 5-HT2 receptor blockade, restores cardiovascular disturbances in type 1 diabetic rats. Diabetes was induced by alloxan (150 mg/kg, s.c.) and maintained for 4 weeks. 5-HT2 receptor was blocked by sarpogrelate (30 mg/kg.day; 14 days; p.o.). Systolic blood pressure (SBP), heart rate (HR), glycaemia and body weight (BW) were monitored periodically. Animals were sacrificed at the end of the study and the heart, right kidney and thoracic aorta were removed; plasma samples were also obtained. Left ventricular hypertrophy index (LVH) and renal hypertrophy index (RH) were determined. Vascular function was studied in aorta rings; additionally, superoxide anion (O2•−) production (by lucigenin-enhanced chemiluminescence) and lipid peroxidation (by thiobarbituric acid reactive substances assay) were measured. Neither alloxan nor sarpogrelate treatments altered HR, LVH or endothelium-independent relaxation. SBP, glycaemia, BW, RH, O2•− production and lipid peroxidation were significantly altered in diabetic animals compared with controls. Sarpogrelate treatment considerably decreased SBP, RH, O2•− production and lipid peroxidation. Endothelium-dependent relaxation was severely reduced in diabetic animal aortas compared to controls; sarpogrelate treatment markedly improved it. Our outcomes show that selectively blocking 5-HT2 receptors has beneficial effects on impaired cardiovascular parameters in diabetes.

Endothelial dysfunction plays a fundamental role in the pathophysiology of diabetes-induced cardiovascular complications, which remain the leading cause of morbidity and mortality in patients with type 1 diabetes (T1D). T1D is a severe and chronic disease characterized by a complete insulin deficiency ending with an extremely high concentration of blood glucose; the hyperglycaemia, as hallmark of diabetes, is involved in the pathogenesis of endothelial dysfunction, which precedes both micro- and macrovascular complications of diabetes1–3. Although insulin therapy attempts to restore normal blood glucose values, it has been shown that even an optimal glycaemic control do not fully protect against, fix or target the cardiovascular complications occurring during T1D4. Therefore, depth knowledge in the mechanisms of cardiovascular diseases and novel approaches to treat cardio and vasculopathies is extremely crucial4–6. In this sense, the serotonergic system stands out for its relevance in the diabetic pathophysiology, since: (i) 5-HT concentrations are altered in diabetes7,8; (ii) 5-HT inhibits the peripheral sympathetic neurotransmission in type 1 diabetic rats9,10; (iii) it has been described an increase in serotonergic peripheral actions, mainly by 5-HT2 receptor activation (increasing platelet aggregation or contractile responses)11–15 and (iv) 5-HT1 receptor activation is involved in an enhanced serotonergic vasocostriction in the type 1 diabetic rat kidney16. Taking into consideration the above-mentioned evidence, 5-HT2 receptor seems to trigger harmful actions at cardiovascular level (whose actions are amplified in T1D). Thus, several investigations have demonstrated that selective 5-HT2 blockade displays protective effects in both T1D and type 2 diabetes17–21; in this study, we aim to determine the impact of modulating the serotonergic system, by the selective blockade of the 5-HT2 receptors (sarpogrelate), on the development of hypertension, cardiac and renal hypertrophy, oxidative stress and endothelial dysfunction in an experimental model of T1D. The rational of our study is based on recent data where our group showed that orally chronic treatment with a selective 5-HT2 antagonist (sarpogrelate; 30 mg/kg.day) exerted cardiovascular favourable actions by enhancing the 5-HT inhibition of the sympathetic neurotransmission22,23, and exhibiting 5-HT vasodilation induced by nitric oxide (NO),
The studied groups (Fig. 1A). However, the renal hypertrophy (RH) index was significantly enhanced in diabetic with alloxan or with sarpogrelate treatment when compared to control rats (Table 1).

Mitigated in the group of diabetic rats treated with sarpogrelate. However, heart rate (HR) was not modified either or the BW when compared with diabetic group (Table 1).

Complications because of chronic hyperglycaemia.

Results
Blood glucose, body weight, heart rate and systolic blood pressure measurements. Alloxan administration elicited a marked increase in blood glucose concentration and decreased body weight (BW) when compared to the normoglycaemic (control) rats. Sarpogrelate treatment did not alter either the hyperglycaemia or the BW when compared with diabetic group (Table 1).

After 28 days of the induction of diabetes the animals reached a hypertensive state (see Table 1), which was mitigated in the group of diabetic rats treated with sarpogrelate. However, heart rate (HR) was not modified either with alloxan or with sarpogrelate treatment when compared to control rats (Table 1).

Cardiac and renal hypertrophy. The left ventricle hypertrophy (LVH) index was not different among all the studied groups (Fig. 1A). However, the renal hypertrophy (RH) index was significantly enhanced in diabetic group vs control group; sarpogrelate treatment was capable of markedly reducing this index (Fig. 1B).

Aortic contractile responses to phenylephrine. The contractile response to phenylephrine (PE; 10^-6 M) in aortic rings was 1756.0 ± 8 mg in control rats; this contraction was significantly higher in non-treated diabetic group, 2225.0 ± 101.2 mg (P < 0.05 vs control rats). Sarpogrelate treatment was able to reduce this increased contractile response in diabetic rats, to the same level as the control group (1862.0 ± 66.9 mg) (P > 0.05 vs control rats) (n = 8 each group).

Endothelium-dependent relaxation in aorta rings. Aortic rings from diabetic rats showed decreased endothelium-dependent vasodilator responses to acetylcholine (ACh), when compared to aortas from normoglycaemic rats. Sarpogrelate treatment produced a significant increase in the relaxation induced by ACh, compared with non-treated diabetic rats (Fig. 2).

After incubation with the combination of indomethacin and tetraethylammonium (TEA), the NO-mediated relaxation was significantly smaller in preparations of diabetic compared to normoglycaemic and sarpogrelate-treated diabetic rats (Fig. 3A). Nevertheless, in the presence of Nω-Nitro-L-arginine methyl ester (L-NAME) plus TEA (COX-mediated relaxation) (Fig. 3B) or L-NAME plus indomethacin (endothelium-dependent hyperpolarization-type relaxation) (Fig. 3C) the ACh response was abolished in all study groups.

Endothelium-independent relaxation in aorta rings. The relaxation induced by sodium nitroprusside (SNP) reached 100% in all groups. No difference was observed in the sensitivity of the aortic arteries to SNP in any of the studied groups (Fig. 4).

Oxidative stress determination. Figure 5 shows the superoxide anion (O_2^-•) production, stimulated by nicotinamide adenine dinucleotide phosphate (NADPH), in aortic rings in all experimental groups. Alloxan-induced diabetes caused a significant increase in the concentration of this free radical. Interestingly, sarpogrelate treatment decreased the amount of O_2^-•, to the same level as the control group.

Similarly, lipid peroxidation, determining the plasmatic malondialdehyde (MDA) levels, significantly increased in non-treated diabetic group (Fig. 6); nonetheless, sarpogrelate treatment was able to strongly reduce this deleterious effect.

Discussion
As outlined in the Introduction section, the goal of the present study was to determine whether the modulation of 5-HT system through the selective blockade of 5-HT_2 receptors (sarpogrelate) could rescue the damaged cardiovascular parameters in T1D. To accomplish our aim, we used alloxan-induced type 1 diabetic rat model.
characterized by a specific necrosis of the pancreatic beta cells ending in insulinopenia and pathologically elevated blood glucose levels9–11,16,25,26.

Serotonergic system plays an important role in the pathophysiology of several cardiovascular disturbances; regarding diabetes, it has been shown that both its concentrations and its receptors are altered, contributing to endothelial damage and, consequently, to the onset or worsening of cardiovascular complications resulting from diabetes7,8,27,28. It has been already demonstrated that alloxan-induced T1D in rats modified the serotonergic influence on peripheral sympathetic and cholinergic neurotransmission9,10,26, as well as on the renal vasculature tone enhancing the 5-HT vasoconstrictor responses mediated by 5-HT2A16. Some investigations have already proven that activation of 5-HT2 receptors play a crucial role in the vasoconstrictor actions and platelet aggregation, evidencing that the antagonism of these serotonergic receptors could exert beneficial actions at cardiovascular level15,17,18,29,30. Sarpogrelate, a selective 5-HT2 receptor antagonist, is used in patients with arteriosclerosis obliterans to improve ischemic symptoms such as ulcer, pain and coldness of the extremities relate to chronic

Figure 1. Cardiac and renal hypertrophy. Relation between the weight of the left ventricle (A) or the weight of kidney (B) and the tibia length, used as left ventricular hypertrophy index (LVH) or renal hypertrophy index (RH), respectively, in normoglycaemic group (Control), diabetic group (D) and sarpogrelate-treated diabetic group (D+Sarp). Values are expressed as mean ± SEM (n = 5–8). *P < 0.05 vs control group. #P < 0.05 vs diabetic group.

Figure 2. Aortic endothelium-dependent relaxation. Relaxation induced by acetylcholine (ACh) in aorta from normoglycaemic group (Control), diabetic group (D) and sarpogrelate-treated diabetic group (D+Sarp). Values are expressed as mean ± SEM (n = 8 each). *P < 0.05 vs control group. #P < 0.05 vs diabetic group.
Figure 3. NO, COX and endothelium-derived hyperpolarization pathways in aortic endothelium-dependent relaxation. Concentration–response curves to acetylcholine (ACh) in the presence of: (A) indomethacin ($10^{-5}$ M) plus TEA ($10^{-4}$ M), (B) L-NAME ($10^{-4}$ M) plus TEA, or (C) L-NAME plus indomethacin in aorta from normoglycaemic group (Control), diabetic group (D) and sarpogrelate-treated diabetic group (D+Sarp). Values are expressed as mean±SEM ($n = 3–5$). *P < 0.05 vs control group. #P < 0.05 vs diabetic group.

Figure 4. Aortic endothelium-independent relaxation. Vascular relaxation to sodium nitroprusside (SNP) in aorta from normoglycaemic group (Control), diabetic group (D) and sarpogrelate-treated diabetic group (D+Sarp). Values are expressed as mean±SEM ($n = 4–7$).
in T1D4,39; our results show that sarpogrelate treatment restored both endothelium-dependent relaxation and vasoconstriction in response to PE. These results are consistent with other studies where both features appeared as shown by the considerable decrease in the endothelial-dependent relaxation to ACh and the increase in the ontonergic inhibition on the peripheral sympathetic neurotransmission22,23, being in agreement with our current research team has demonstrated that sarpogrelate treatment in normoglycaemic rats caused: (i) a potentiation of peripheral sympatho-inhibition by serotonergic system22,23, and (ii) exhibited to 5-HT as an exclusively vasodilator agent in the kidney24, confirming that the 5-HT2 blockade seems to have positive effects on cardiovascular level.

Cardiovascular risk in T1D associated with hypertension is substantially enhanced2,31. In fact, chronic hyperglycaemia can trigger hypertension and, therefore, an increase in damage on the target organs (blood vessels, kidney and retina, among others). In our experimental model, T1D for 28-days duration reached an incipient hypertensive state (without modifying heart rate) compared with normoglycaemic rats; interestingly, sarpogrelate treatment significantly reduced the increase in the systolic blood pressure (SBP). Although the beneficial effect of sarpogrelate treatment on the cardiovascular system has been well documented, its antihypertensive effect has not been reported elsewhere22,23; nevertheless, our findings show that blocking 5-HT2 receptors during 14 days with sarpogrelate exerts a protective effect on the onset of hypertension in T1D.

In order to assess the early onset of diabetic cardiomyopathy and nephropathy, we study LVH and RH, respectively. Substantial changes were not observed in LVH in the diabetic groups compared to control animals, which can be probably attributed to the fact that the duration of diabetes is not sufficient to trigger hypertrophy of the left ventricle. However, RH was significantly increased in non-treated diabetic rats, which may be related to an incipient diabetic nephropathy; sarpogrelate treatment was able to reverse RH in diabetic rats. This result is in agreement with several studies showing that sarpogrelate offers beneficial actions in the renal pathology derived from diabetes19,33–35; additionally, previous data by us24 demonstrated that sarpogrelate is able to exhibit exclusively the vasodilator serotonergic action in the rat kidney, which may also contribute to ameliorate the renal function. The rescue of the kidney hypertrophy by sarpogrelate treatment could help to the reduction of the hypertension state and, as a whole, the onset of diabetic nephropathy.

On the other hand, neither hyperglycaemia nor BW evolution were modified by sarpogrelate treatment in type 1 diabetic rats. Conversely, other authors, in different experimental models of type 2 diabetes, have established that oral sarpogrelate treatment did improve glycaemia of diabetic rats36,37. Thus, we suggest that pharmacological benefits observed in diabetic rats treated with sarpogrelate are not due to the improvement of blood glucose levels in our experimental model.

Diabetes-triggered alterations in vascular reactivity in a conduit vessel such as the aorta have an important pathophysiological relevance because of modifications in blood flow to the heart and/or more distal peripheral blood vessels38. In our experimental conditions, the endothelial function in diabetic rats was deteriorated as shown by the considerable decrease in the endothelial-dependent relaxation to ACh and the increase in the vasoconstriction in response to PE. These results are consistent with other studies where both features appeared in T1D4,39; our results show that sarpogrelate treatment restored both endothelium-dependent relaxation and vasoconstrictor responses in diabetic animals.

It has been established that diabetes is associated with adrenergic hyperactivity leading to worsening of cardiovascular disorders40 which can explain the increase in the vasoconstrictor responses shown in our diabetic rats; on the other hand, previous studies have already demonstrated that sarpogrelate treatment potentiated the serotonergic inhibition on the peripheral sympathetic neurotransmission22,23, being in agreement with our current data where sarpogrelate treatment stops such sympathetic overactivity in diabetic rats.

Although this impaired endothelial function is mainly characterized by decreased release of NO39,41, COX-derived prostaglandins or endothelium-dependent hyperpolarization also play an important role in the endothelium-dependent relaxation32–44. However, our data indicate that endothelium-dependent relaxation mediated by COX pathway or endothelium-dependent hyperpolarization are not involved in the vasodilator effect of our three experimental groups. NO pathway was the main implicated in the endothelium-dependent relaxation and was strikingly impaired in diabetic rats; interestingly, sarpogrelate treatment potentiated the NO pathway, improving significantly the vasodilator action, in diabetic rats. These outcomes are consistent with other studies that establish that 5-HT2 blockade improved the role of NO in diabetic mice45, and in non-diabetic canine46, rat47.

![Figure 5. Superoxide anion determination.](image)

Vascular superoxide anion (O2•−) level expressed as relative luminescence units (RLU)/min/mg dry tissue stimulated by NADPH addition in aortic rings from normoglycaemic group (Control), diabetic group (D) and sarpogrelate-treated diabetic group (D+Sarp). Values are expressed as mean ± SEM (n = 6). *P < 0.05 vs control group. #P < 0.05 vs diabetic group.
rabbit or guinea-pig, and with previous studies where sarpogrelate treatment enhanced endothelial NO synthase expression in rats.

Semaming et al. have already established that the endothelium-independent relaxation by SNP was damage in streptozotocin-induced T1D (6-weeks duration) in Sprague-Dawley rats, however our T1D model demonstrates that endothelial-independent relaxation induced by SNP was not affected either by alloxan administration or by treatment with sarpogrelate, which allows us to rule out an alteration on the vascular smooth muscle. What is more, these results are in agreement with several authors reporting no impairment in endothelium-independent relaxation.

On this basis, these findings confirm that blocking selectively 5-HT serotonergic receptor improves endothelial function throughout NO bioavailability in alloxan-induced T1D.

Strong evidences point out an intimate association between long-time hyperglycaemia and overproduction of reactive oxygen species (ROS), which significantly contribute to the generation of both micro- and macrovascular diabetes complications. In this sense, our T1D model was associated with a significant increase in both $O_2^\cdot$ production in aortic arteries and lipid peroxidation compared to normoglycaemic rats. Interestingly, sarpogrelate treatment was able to considerably reduce the ROS as well as the plasma levels of MDA in alloxan-induced T1D. These findings are consistent with other studies where sarpogrelate demonstrated the ability to attenuate oxidative stress. Thus, taking into account these results, we could state that sarpogrelate has antioxidant properties, decreasing hyperglycaemia-induced oxidative stress. Therefore, sarpogrelate could occupy an important place in the new pharmacological approach moderating the levels of free radicals, as already reported for other compounds such as antioxidants, statins or angiotensin-converting enzyme inhibitors.

Given that: (i) diabetic vasculopathies are the leading causes of morbidity and mortality in T1D; (ii) despite having a suitable glycaemic control, this is not sufficient for the prevention and treatment of cardiovascular pathologies resulting from diabetes; (iii) our current outcomes exhibit that blocking selectively 5-HT receptors in T1D rats improves not only the endothelial function but also vascular abnormalities produced by chronic hyperglycaemia (development of hypertension and increased kidney hypertrophy, $O_2^\cdot$ production and lipid peroxidation); (iv) it has been reported that 5-HT receptor antagonists are more effective than COX inhibitors in preventing cardiovascular events in diabetic patients; and (v) it has been established that sarpogrelate exerts pleiotropic effect on the vasculature resulting in the improvement of endothelial function in diabetic angiopathy, we could state that selective blockade of 5-HT serotonergic receptors in T1D may be an useful therapeutic strategy to prevent or treat the alterations that initiate long-term cardiovascular complications.

Further studies will be required to determine whether sarpogrelate treatment may improve micro- and macrovascular disturbances derived from experimental long-term T1D, in order to confirm whether the selective 5-HT receptor blockade is a key therapeutic target in the treatment and/or prevention of cardiovascular complications resulting from chronic hyperglycaemia.

In conclusion, our findings suggest that blocking selectively 5-HT serotonergic receptor significantly improves endothelial function, alleviates the development of hypertension, renal hypertrophy and reduces oxidative stress. Therefore, this study supports that sarpogrelate treatment could establish an innovative therapeutic goal in the prevention and treatment of cardiovascular complications as consequence of diabetes.

**Methods**

**Ethics in the study protocol.** Housing conditions and experimental procedures were in accordance with regulations provided by the European Union on the use of animals for scientific purposes (2010/63/UE). This was enacted by Spanish legislation on 1st February 2013 (R.D. 53/2013). All protocols were approved by the University of Salamanca Institutional Bioethics Committee (006N°201400037278).

**Compounds.** The compounds utilized in the present study were: sarpogrelate hydrochloride was from ABBLIS Chemical LLC (Houston TX, US); ACh chloride, alloxan monohydrate, pentobarbital sodium, PE hydrochloride, indomethacin, L-NAME hydrochloride, SNP, thiobarbituric, tricloroacetic acid, N,N-dimethyl-9,9-biacridinium dinitrate (lucigenin), NADPH and ammonium diethyldithiocarbamate (DDC) were purchased.
from Sigma-Aldrich (Spain). TEA chloride was purchased from Tocris Bioscience (Bristol, UK). MDA bis-(dime-thyl acetal) was purchased from Merk (Darmstadt, Germany). All other chemicals were of analytical grade. Stock solutions of the drugs were made up in ultrapure water, stored at −20°C and appropriate dilutions were made on the day of the experiments.

Animals. Twenty-four male Wistar rats (335 ± 10 g) were used in the present study. Rats were kept and supplied by the Animal House of the Faculty of Pharmacy of the University of Salamanca (PAE-SA001; Salamanca, Spain).

The animals were divided into three groups: normoglycaemic, diabetic and sarpogrelate-treated diabetic rats (n = 8 each). Diabetes was induced by a single injection of alloxan (150 mg/kg, s.c.) dissolved in saline solution. Rats were then maintained on tap water and regular food ad libitum for 28 days. Normoglycaemic rats received saline (1 ml/kg, s.c.), serving as controls. Non-fasting blood glucose levels, BW, HR and SBP were determined before and at 2, 7, 14, 21 and 28 days after alloxan (diabetic groups) or saline (control group) administration. Only rats with elevated blood glucose levels (>11 mM) were considered diabetic. Non-fasting blood glucose levels were determined by a glucometer (Accutrend Sensor®; Roche Diagnostics; Germany). SBP and HR were measured in awake rat using the tail-cuff method with a photoelectric sensor (NIPREM 546, Cibertec S.A, Madrid, Spain), where some determinations were made in each session for each animal, considering valid whether five consecutive measurements did not vary by 10 mmHg.

Sarpogrelate was administered dissolved in drinking water (30 mg/kg/day; p.o.), starting at 14 days of induction of TID (i.e. during 14 days)22-24; in sarpogrelate-treated diabetic group.

At the end of the treatments (28 days), rats were anaesthetised with sodium pentobarbital (60 mg/kg, i.p.) and blood samples were collected. Then, thoracic aorta artery, heart and right kidney were extracted and placed in Krebs solution of the following composition (in mM): NaCl, 118; KCl, 4.7; CaCl2, 2.5; KH2PO4, 1.2; MgSO4·7H2O, 1.2; NaHCO3, 25 and glucose, 11 (pH = 7.4), and appropriately processed for further studies. Blood samples were centrifuged at 350 g for 10 min, at 4°C, to obtain the plasma which was kept at −80°C until use.

Organs hypertrophy. The heart was removed and placed immediately in Krebs solution at 37°C gassed with carbogen (5% CO2, 95% O2) to remove excess blood and subsequently kept at chilled Krebs. The atria were removed from the heart and all the epicardial fat was scraped off. The right and the left ventricle were separated, regarding the interventricular septum as an integral part of the left ventricle, and this portion was weighed. The LVH index was calculated using left ventricle weight/tibia length ratio (mg/mm).

The right kidney was dissected and fat separated. The RH index was calculated using kidney weight/tibia length ratio (mg/mm).

Vascular reactivity. The thoracic aorta was carefully cleaned of fat and connective tissue and cut into rings (3 mm length) and placed in organ baths as we have indicated elsewhere by Kassan et al.60. The functional integrity of the endothelium was checked by assessing the relaxant response to ACh (10−6 M) in rings pre-contracted with PE (10−6 M). After a washout period, arteries were pre-contracted with PE (10−4 M) and at the steady maximal contraction, cumulative concentration-response curves to ACh (10−8 to 10−4 M) were performed in the absence and presence of pharmacological inhibitors: (1) NO-mediated relaxations: rings were incubated with the combination of indomethacin (10−6 M; a non-selective inhibitor of COX), plus TEA (10−4 M; a non-selective K+ channel blocker); (2) endothelium-dependent hyperpolarization-type relaxations: rings were incubated with indomethacin plus L-NAME (10−4 M; NO synthase inhibitor); and (3) prostacyclin-mediated relaxations: rings were incubated with L-NAME plus TEA. The preparations were incubated with the appropriate inhibitors for 30 min before the PE pre-contraction.

Endothelium-independent relaxation of the aortic arteries was assessed by pre-contracting with PE (10−6 M) followed by cumulative addition of SNP (10−9 to 10−4 M).

The responses to ACh and SNP are expressed as percentage of PE pre-contraction, and the responses to PE are represented as mg of contraction.

Detection of vascular superoxide anion. O2•− production was assessed by lucigenin-enhanced chemiluminescence assay. Briefly, segments of thoracic aorta were incubated in ROS Phosphate buffer (composition in mM: KH2PO4, 50; EGTA, 1 and Sucrose, 150, pH = 7.4) gassed with carbogen and maintained at 37°C for 15 min. Then, samples were transferred into tubes containing ROS phosphate buffer supplemented with DDC (10 mM), NADPH (10−4 M) and lucigenin (5 μM). Lucigenin chemiluminescence was then recorded every 10 s for 5 min in a luminometer (LUMAT LB-9507, Berthold Technologies, Bad Wildbad, Germany). Production of O2•− is expressed as relative luminescence units (RLU)/min/mg tissue.

Lipid peroxidation measurement. Lipid peroxidation, a marker of oxidative stress, was determined by measuring the plasmatic MDA levels through the thiobarbituric acid reactive substances (TBARS) method, used by Kassan et al.60. Data are expressed as concentration of MDA, nmol/ml.

Statistical procedures. All data are shown as mean ± SEM. Concentration–response curves were analysed using the GraphPad Prism 5.0 software (GraphPad, USA). Statistical analysis for significant differences between the different groups were performed with one-way analysis of variance (ANOVA) followed by the post hoc Bonferroni’s test. Significance was accepted at P < 0.05.
References

1. Stadler, M. et al. Persistent arterial stiffness and endothelial dysfunction following successful pancreas-kidney transplantation in Type 1 diabetes. Diabet. Med. 26, 1010–1018 (2009).
2. Schnell, O. et al. Type 1 diabetes and cardiovascular disease. Cardiovasc. Diabetol. 12, 156–166 (2013).
3. Ladeia, A. M., Sampaio, R. R., Hita, M. C. & Adam, L. F. Prognostic value of endothelial dysfunction in type 1 diabetes mellitus. *World J. Diabetes*, 5, 601–605 (2014).
4. Cerillo, A. et al. The simultaneous control of hyperglycemia and GLP-1 infusion normalize endothelial function in type 1 diabetes. *Diabetes Res. Clin. Pract.* 114, 64–68 (2016).
5. Garg, V. Noninsulin pharmacological management of type 1 diabetes mellitus. *Indian J. Endocrinol. Metab.* 15, SS–S11 (2011).
6. Cinar, M. G., Ulker, S., Alper, G. & Evinc, A. Effect of dietary vitamin E supplementation on vascular reactivity of thoracic aorta in streptozotocin-diabetic rats. *Pharmacology* 62, 58–64 (2001).
7. Sandrin, M., Vitale, G., Vergoni, A. V., Ottani, A. & Bertoloni, A. Streptozotocin-induced diabetes provokes changes in serotonin concentration and on 5-HT1A and 5-HT2 receptors in the rat brain. *Life Sci.* 60, 1393–1397 (1997).
8. Haider, S. et al. Sulfotransferase-induced serotonin deficiency leads to development of behavioral deficits in rats. *Acta Neurol. Belg.* 113, 35–41 (2013).
9. García, M., Morán, A., Martín, M. L., Barthelmebs, M. & San Román, L. The nitric oxide synthesis/pathway mediates the inhibitory serotonergic responses of the pressor effect elicited by sympathetic stimulation in diabetic pithed rats. *Eur. J. Pharmacol.* 537, 126–134 (2006).
10. Restrepo, B. et al. The cyclooxygenase and nitric oxide synthesis/pathways mediate the inhibitory serotonergic response to the pressor effect elicited by sympathetic stimulation in long-term diabetic pithed rats. *Pharmacology* 90, 169–176 (2012).
11. Miranda, F. J. et al. Experimental diabetes induces hyperreactivity of rabbit renal artery to 5-hydroxytryptamine. *Eur. J. Pharmacol.* 439, 121–127 (2002).
12. Bagwell, C. A. & Brophy, C. Enhanced arterial contractile responses in diabetic hypercholesterolemic pig carotid arteries. *Int. J. Surg. Investig.* 1, 477–481 (2000).
13. Bir, S. C. et al. New therapeutic approach for impaired arteriogenics in diabetic mouse hindlimb ischemia. *Circ. J.* 72, 833–640 (2008).
14. Nuno, D. W. & Lamping, K. G. The role of rho kinase in sex-dependent vascular dysfunction in type 1 diabetes. *Exp. Diabetes Res.* 2010, 176361, doi: 10.1155/2010/176361 (2010).
15. Yamada, K., Niki, H., Nagai, H., Nishikawa, M. & Nakagawa, H. Serotonin potentiates high-glucose-induced endothelial injury: the role of serotonin and 5-HT(2A) receptors in promoting thrombosis in diabetes. *J. Pharmacol. Sci.* 119, 243–250 (2012).
16. Restrepo, B. et al. Participation of cyclooxygenase pathway in the vasconstriction induced by 5-HT in the in situ aortofemoral kidney of long-term diabetic rats. *Eur. J. Pharmacol.* 659, 37–44 (2011).
17. Saini, H. K. et al. Therapeutic potentials of sarpogrelate in cardiovascular disease. *Cardiovasc. Drug Rev.* 22, 27–54 (2004).
18. Garcia-Pedraza, J. A. et al. Peripheral 5-HT1D and 5-HT7 serotonergic receptors modulate sympathetic neurotransmission in chronic sarpogrelate treated rats. *Eur. J. Pharmacol.* 714, 65–73 (2013)
19. Garcia-Pedraza, J. A., Garcia, M., Martin, M. L., San Roman, L. & Moran, A. The role of endothelium-derived hyperpolarizing factor and cyclooxygenase pathways in the inhibitory serotonergic response to the pressor effect elicited by sympathetic stimulation in chronic sarpogrelate treated rats. *Eur. J. Pharmacol.* 731, 80–87 (2014).
20. García-Pedraza, J. A., García, M., Martín, M. L., Rodríguez-Barbero, A. & Morán, A. 5-HT2 receptor antagonist blockades 5-HT vasodilator effects via nitric oxide, prostacyclin and ATP-sensitive potassium channels in rat renal vasculature. *Vasc. Pharmacol.* 79, 51–59 (2016).
21. Lenzen, S. The mechanisms of allaxon- and streptozotocin-induced diabetes. *Diabetologia* 51, 216–226 (2008).
22. Restrepo, B., Martin, M. L., San Román, L. & Morán, A. Peripheral 5-HT1A and 5-HT7 serotonergic receptors modulate parasympathetic neurotransmission in long-term diabetic rats. *Exp. Diabetes Res.* 2010, 686734, doi: 10.1155/2010/686734 (2010).
23. Haru, K., Hirowatari, Y., Shimura, Y. & Takahashi, H. Serotonin levels in platelet-poor plasma and whole blood in people with type 2 diabetes with chronic kidney disease. *Diabetes Res. Clin. Pract.* 77, 167–171 (2010).
24. Yanai, H. & Hirowatari, Y. A significant association of plasma serotonin to cardiovascular risk factors and changes in pulse wave velocity in patients with type 2 diabetes. *Int. J. Cardiol.* 157, 312–313 (2012).
25. Nagatomo, T., Rashid, M., Ablu Muntasir, H. & Komiyama, T. Functions of 5-HT2A receptor and its antagonists in the cardiovascular system. *Pharmacol. Ther.* 104, 59–81 (2004).
26. Sonawane, R. D. et al. Role of 5-HT2 receptors in diabetes: Swertiajamar secoiridoid glycoside might be a possible 5-HT2 receptor modulator. *Physiol. Behav.* 144, 66–72 (2015).
27. Libby, P. et al. Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus. *Circulation* 111, 3489–3493 (2005).
28. Setoguchi, Y. et al. Effects of chronic administration of sarpogrelate on systolic blood pressure of spontaneously hypertensive rats: comparison with quinapril. *Pharmacology* 64, 71–75 (2002).
29. Hamaasaki, Y. et al. A 5-hydroxytryptamine receptor antagonist, sarpogrelate, reduces renal tubulointerstitial fibrosis by suppressing PAI-1. *Am. J. Physiol. Renal Physiol.* 305, F1796–F1803 (2013).
30. Lee, S. A. et al. Study design of the influence of Serootonin inhibition on patients with RENAl impairment or diabetes undergoing drug-eluting stent implantation (SERENADE) study: A multicenter, open-label, prospective, randomized study. *Contemp. Clin. Trials* 43, 20–24 (2015).
31. Kim, D. H. et al. Beneficial Effects of Sarpogrelate and Rosuvastatin in High Fat Diet/Streptozotocin-Induced Nephropathy in Mice. *PLoS One* 11, e0153965, doi: 10.1371/journal.pone.0153965 (2016).
32. Ma, S. et al. Effective treatment with combination of peripheral 5-hydroxytryptamine synthetic inhibitor and 5-hydroxytryptamine 2 receptor antagonist on glucocorticoid-induced whole-body insulin resistance with hyperglycemia. *J. Diabetes Investig.* doi: 10.1111/jdi.12526 (2016).
33. Takahata, E. et al. Effect of sarpogrelate hydrochloride, a 5-HT2 blocker, on insulin secretion in Otsuka Long-Evans Tokushima fatty rats (OLETF rats), a type 2 diabetic rat model. *J. Cardiovasc. Pharmacol.* 43, 266–270 (2004).
34. Christi, G., Valcic, M. & Gondec, M. C. Augmentation in the kinetic characteristics of phenylephrine- and 5-hydroxytryptamine-induced contractions in the isolated rat aorta following eight weeks of STZ-diabetes. *Life Sci.* 55, 807–814 (1994).
35. El-Bassossy, H. M., Elberry, A. A. & Ghareib, S. A. Geraniol improves the impaired vascular reactivity in diabetes and metabolic syndrome through calcium channel blocking effect. *J. Diabetes Complications*, doi: 10.1016/j.diabcomp.2016.04.006 (2016).
36. Perin, P. C., Maule, S. & Quadri, R. Sympathetic nervous system, diabetes, and hypertension. *Clin. Exp. Hypertens.* 23, 45–55 (2001).
41. Delbin, M. A. & Trask, A. J. The diabetic vasculature: physiological mechanisms of dysfunction and influence of aerobic exercise training in animal models. *Life Sci.* 102, 1–9 (2014).
42. Dabisch, P. A. et al. Role of potassium channels in the nitric oxide-independent vasodilator response to acetylcholine. *Pharmacol. Res.* 49, 207–215 (2004).
43. Takáci, A. et al. Roles of endothelial oxidases in endothelium-derived hyperpolarizing factor responses in mice. *J. Cardiovasc. Pharmacol.* 52, 510–517 (2008).
44. Zhang, L. N. et al. Inhibition of soluble epoxide hydrolase attenuates endothelial dysfunction in animal models of diabetes, obesity and hypertension. *Eur. J. Pharmacol.* 654, 68–74 (2011).
45. Iwabayashi, M. et al. Role of serotonin in angiogenesis: induction of angiogenesis by sarpgrelate via endothelial 5-HT1B/ATk/eNOS pathway in diabetic mice. *Atherosclerosis* 220, 337–342 (2012).
46. Fujita, M. et al. Selective blockade of serotonin 5-HT2A receptor increases coronary blood flow via augmented cardiac nitric oxide release through 5-HT1B receptor in hypoperfused canine hearts. *J. Mol. Cell Cardiol.* 37, 1219–1223 (2004).
47. Zhang, E. et al. Sarpgrelate hydrochloride, a serotonin 5HT2A receptor antagonist, ameliorates the development of chronic hypoxic pulmonary hypertension in rats. *J. Anesth.* 29, 715–723 (2015).
48. Kodama, A. et al. Sarpgrelate hydrochloride reduced intimal hyperplasia in experimental rabbit vein graft. *J. Vasc. Surg.* 49, 1272–1281 (2009).
49. Muto, T. et al. Protective effects of sarpgrelate, a 5-HT2A antagonist, against postischemic myocardial dysfunction in guinea-pig hearts. *Mol. Cell Biochem.* 272, 119–132 (2005).
50. Semaming, Y., Kukongviriyapan, U., Kongyingyoes, B., Thukhammee, W. & Pannangpetch, P. Protocatechuic acid restores vascular responses in rats with chronic diabetes induced by streptozotocin. *Phytother. Res.* 30, 227–233 (2016).
51. Li, X. F., Wan, T. T., Sun, Y. M. & Su, Y. Na+/Ca2+ exchanger inhibitor restores endothelium-dependent relaxation in diabetic rat aorta. *Exp. Clin. Endocrinol. Diabetes* 123, 394–397 (2015).
52. Mokhtar, S. S. et al. Reduced nitric oxide-mediated relaxation and endothelial nitric oxide synthase expression in the tail arteries of streptozotocin-induced diabetic rats. *Eur. J. Pharmacol.* 773, 78–84 (2016).
53. Kaneto, H. et al. Involvement of oxidative stress in the pathogenesis of diabetes. *Antioxid. Redox Signal* 9, 355–366 (2007).
54. Xu, Y. J. et al. Suppression of high lipid diet induced by atherosclerosis sarpgrelate. *J. Cell Mol. Med.* 16, 2394–2400 (2012).
55. Rochette, L., Zeller, M., Cottin, Y. & Vergely, C. Diabetes, oxidative stress and therapeutic strategies. *Biochim. Biophys. Acta.* 1840, 2709–2729 (2014).
56. Frandsen, C. S., Deigaard, T. F. & Madshod, S. Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus. *Lancet Diabetes Endocrinol.* doi: 10.1016/S2213-8587(16)00039-5 (2016).
57. Forbes, J. M. & Cooper, M. E. Mechanisms of diabetic complications. *Physiol. Rev.* 93, 137–188 (2013).
58. Shinozaka, Y. et al. Sarpgrelate versus aspirin in secondary prevention of cerebral infarction differential efficacy in diabetes? Subgroup analysis from SACCCESS. *Stroke* 40, 2862–2865 (2009).
59. Nagayama, D., Ohira, M., Saiki, A., Shirai, K. & Tatsuno, I. Sarpgrelate hydrochloride decreases cardio-ankle vascular index accompanied by increased serum lipoprotein lipase mass in type 2 diabetic patients. *Int. Heart J.* 55, 337–341 (2014).
60. Kassan, M., Montero, M. J. & Sevilla, M. A. Chronic treatment with pravastatin prevents early cardiovascular changes in spontaneously hypertensive rats. *Br. J. Pharmacol.* 158, 541–547 (2009).

**Acknowledgements**

The authors thank Junta de Castilla y León (Projects SA147U13 and BIO/SA62/14) for financial support. J.-Á. García-Pedraza is supported by Junta de Castilla y León and European Social Fund, budgeting application no. 322C1400.

**Author Contributions**

M.-J.M. and A.M. proposed the hypothesis and designed the experiments. J.-Á.G.-P., P.F.-S. and R.A. carried out all the experimental procedures. P.F.-S., R.A. and M.-J.M. performed the data analysis. J.A.G.-P. and A.M. wrote the manuscript. All authors read and approved the final manuscript.

**Additional Information**

**Competing financial interests:** The authors declare no competing financial interests.

**How to cite this article:** García-Pedraza, J.-Á. *et al.* Blocking 5-HT2 receptor restores cardiovascular disorders in type 1 experimental diabetes. *Sci. Rep.* 6, 33979; doi: 10.1038/srep33979 (2016).